Last reviewed · How we verify

Diuretic Increase (DI) — Competitive Intelligence Brief

Diuretic Increase (DI) (Diuretic Increase (DI)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Cardiovascular.

marketed Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Diuretic Increase (DI) (Diuretic Increase (DI)) — Medtronic BRC. Diuretic Increase (DI) is a device-based therapy from Medtronic that enhances diuretic efficacy, likely through optimized drug delivery or physiological modulation to increase urine output.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Diuretic Increase (DI) TARGET Diuretic Increase (DI) Medtronic BRC marketed

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Diuretic Increase (DI) — Competitive Intelligence Brief. https://druglandscape.com/ci/diuretic-increase-di. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing